Hepatocellular carcinoma: perfusion quantification with dynamic contrast-enhanced MRI.
暂无分享,去创建一个
H. Rusinek | B. Taouli | M. Merad | C. Hajdu | H. Yee | M. Oei | R. Johnson | R. Scott Johnson | Cristina H. Hajdu | Marcel T. H. Oei
[1] Edward Ashton,et al. Dynamic Contrast-Enhanced Magnetic Resonance Imaging , 2012, Definitions.
[2] Tao Jiang,et al. Monitoring Response to Antiangiogenic Treatment and Predicting Outcomes in Advanced Hepatocellular Carcinoma Using Image Biomarkers, CT Perfusion, Tumor Density, and Tumor Size (RECIST) , 2012, Investigative radiology.
[3] M. Mulcahy,et al. Intraprocedural transcatheter intra-arterial perfusion MRI as a predictor of tumor response to chemoembolization for hepatocellular carcinoma. , 2011, Academic radiology.
[4] J. Bruix,et al. Management of hepatocellular carcinoma: An update , 2011, Hepatology.
[5] Lawrence H. Schwartz,et al. Antiangiogenic Therapy for Primary Liver Cancer: Correlation of Changes in Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Tissue Hypoxia Markers and Clinical Response , 2011, Annals of Surgical Oncology.
[6] G. Baron,et al. Liver fibrosis in chronic hepatitis C virus infection: differentiating minimal from intermediate fibrosis with perfusion CT. , 2010, Radiology.
[7] H. Rusinek,et al. Diagnosis of cirrhosis with intravoxel incoherent motion diffusion MRI and dynamic contrast‐enhanced MRI alone and in combination: Preliminary experience , 2010, Journal of magnetic resonance imaging : JMRI.
[8] T. Roskams,et al. Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. , 2010, Seminars in liver disease.
[9] L. Schwartz,et al. Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] F. Fazio,et al. Perfusion Computed Tomographic Assessment of Early Hepatocellular Carcinoma in Cirrhotic Liver Disease: Initial Observations , 2008, Journal of computer assisted tomography.
[11] C. Thng,et al. Hepatic metastases: in vivo assessment of perfusion parameters at dynamic contrast-enhanced MR imaging with dual-input two-compartment tracer kinetics model. , 2008, Radiology.
[12] J. Mabrut,et al. Characterization of hepatocellular carcinoma and colorectal liver metastasis by means of perfusion MRI , 2008, Journal of magnetic resonance imaging : JMRI.
[13] Dieter Häussinger,et al. Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.
[14] D. Collins,et al. Quantitative mapping of hepatic perfusion index using MR imaging: a potential reproducible tool for assessing tumour response to treatment with the antiangiogenic compound BIBF 1120, a potent triple angiokinase inhibitor , 2008, European Radiology.
[15] H. Rusinek,et al. Advanced liver fibrosis: diagnosis with 3D whole-liver perfusion MR imaging--initial experience. , 2008, Radiology.
[16] Henry Rusinek,et al. Quantitative determination of Gd‐DTPA concentration in T1‐weighted MR renography studies , 2007, Magnetic resonance in medicine.
[17] N. Holalkere,et al. Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue--initial experience. , 2007, Radiology.
[18] D. Amadori,et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] A. Kirsch,et al. Dynamic contrast-enhanced MR urography in the evaluation of pediatric hydronephrosis: Part 1, functional assessment. , 2005, AJR. American journal of roentgenology.
[20] R. O'Gorman,et al. Comparison of the hepatic perfusion index measured with gadolinium-enhanced volumetric MRI in controls and in patients with colorectal cancer. , 2005, The British journal of radiology.
[21] J. Bruix,et al. Chemoembolization for hepatocellular carcinoma. , 2004, Gastroenterology.
[22] Jane Wang,et al. Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepatocellular carcinoma treated with an antiangiogenic agent: a preliminary study. , 2004, AJR. American journal of roentgenology.
[23] B. V. Van Beers,et al. Hepatic flow parameters measured with MR imaging and Doppler US: correlations with degree of cirrhosis and portal hypertension. , 2003, Radiology.
[24] C. Sempoux,et al. Capillarization of the sinusoids in liver fibrosis: Noninvasive assessment with contrast‐enhanced MRI in the rabbit , 2003, Magnetic resonance in medicine.
[25] A. Padhani. Dynamic contrast‐enhanced MRI in clinical oncology: Current status and future directions , 2002, Journal of magnetic resonance imaging : JMRI.
[26] B. V. Van Beers,et al. Assessment of hepatic perfusion parameters with dynamic MRI , 2002, Magnetic resonance in medicine.
[27] S. Fan,et al. Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. , 2001, American journal of clinical pathology.
[28] R Materne,et al. Hepatic perfusion parameters in chronic liver disease: dynamic CT measurements correlated with disease severity. , 2001, AJR. American journal of roentgenology.
[29] A. Padhani. Dynamic contrast-enhanced MRI studies in human tumours. , 1999, The British journal of radiology.
[30] K. Plate,et al. Vascular endothelial growth factor , 1997, Journal of Neuro-Oncology.
[31] A R Padhani,et al. Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics , 1997, Journal of magnetic resonance imaging : JMRI.
[32] E. Rostrup,et al. Myocardial perfusion modeling using MRI , 1996, Magnetic resonance in medicine.
[33] H. Dvorak,et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.
[34] D. Connolly. Vascular permeability factor: A unique regulator of blood vessel function , 1991, Journal of cellular biochemistry.
[35] M. Kojiro,et al. Pathologic Characteristics of Hepatocellular Carcinoma , 1986, Seminars in liver disease.
[36] J. Kao,et al. Dynamic contrast-enhanced magnetic resonance imaging with Gd-EOB-DTPA for the evaluation of liver fibrosis in chronic hepatitis patients , 2011, European Radiology.
[37] F. Fazio,et al. Perfusion CT in cirrhotic patients with early stage hepatocellular carcinoma: assessment of tumor-related vascularization. , 2010, European journal of radiology.
[38] H. Naora,et al. Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma: a comparison with angiopoietin/Tie pathway. , 2002, Anticancer research.